New combo therapy battles returning blood cancer in major trial
NCT ID NCT07463807
Summary
This study is for adults with multiple myeloma (a blood cancer) that has come back after one or two prior treatments. It aims to see if a new two-drug combination (teclistamab and pomalidomide) is safer and works better than a standard three-drug combination. Researchers will check if the new combo can reduce cancer cells to undetectable levels and help patients live longer without the disease getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.